No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 173 | 173 | 205 | 231 | 259 | 278 | 332 | N/A | N/A |
| Operating profit | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | $m | 8 | 8 | 11 | 11 | 14 | 15 | 5 | N/A | N/A |
| EPS reported | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | $m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | $ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Value | ||||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | ||||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | ||||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | ||||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | Locked | Locked | Locked |
| Environmental score | Locked | Locked | Locked |
| Social score | Locked | Locked | Locked |
| Governance score | Locked | Locked | Locked |
| Risk rating | Locked | Locked | Locked |
Company overview
Transcat, Inc. offers comprehensive calibration and instrument services for laboratories, serving clients across the United States, Canada, and other international markets. The company operates through two distinct divisions: Service and Distribution. The Service division delivers a wide array of offerings, including precision calibration, equipment repair, thorough inspections, analytical qualification, preventive maintenance, and expert consulting. This segment also features its proprietary software, CalTrak, designed to manage documents and assets while streamlining the operational workflow for its calibration centers and customer equipment. Additionally, its "Compliance, Control and Cost" online portal grants customers web-based asset management capabilities and a secure, off-site repository for calibration and other service records. The Distribution division focuses on the sale and rental of instruments for testing, measurement, and control purposes. It also provides valuable supplementary services such as the calibration and certification of newly purchased equipment, equipment leasing, sales of pre-owned machinery, and customized equipment kitting. This division engages customers through its online platform, various digital and print marketing campaigns, proactive outbound sales efforts, and an incoming call center. Transcat primarily caters to highly regulated sectors, particularly the life sciences—encompassing pharmaceutical, biotechnology, medical device, and other FDA-regulated entities. Furthermore, it extends its services and products to aerospace and defense, industrial manufacturing, energy, utilities, and other industries where process accuracy and confirmed equipment performance are paramount. Established in 1964, Transcat, Inc. maintains its corporate headquarters in Rochester, New York.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Transcat, Inc. offers comprehensive calibration and instrument services for laboratories, serving clients across the United States, Canada, and other international markets. The company operates through two distinct divisions: Service and Distribution. The Service division delivers a wide array of offerings, including precision calibration, equipment repair, thorough inspections, analytical qualification, preventive maintenance, and expert consulting. This segment also features its proprietary software, CalTrak, designed to manage documents and assets while streamlining the operational workflow for its calibration centers and customer equipment. Additionally, its "Compliance, Control and Cost" online portal grants customers web-based asset management capabilities and a secure, off-site repository for calibration and other service records. The Distribution division focuses on the sale and rental of instruments for testing, measurement, and control purposes. It also provides valuable supplementary services such as the calibration and certification of newly purchased equipment, equipment leasing, sales of pre-owned machinery, and customized equipment kitting. This division engages customers through its online platform, various digital and print marketing campaigns, proactive outbound sales efforts, and an incoming call center. Transcat primarily caters to highly regulated sectors, particularly the life sciences—encompassing pharmaceutical, biotechnology, medical device, and other FDA-regulated entities. Furthermore, it extends its services and products to aerospace and defense, industrial manufacturing, energy, utilities, and other industries where process accuracy and confirmed equipment performance are paramount. Established in 1964, Transcat, Inc. maintains its corporate headquarters in Rochester, New York.